Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

CSCC

- PMLiVE

Success for AZ, setback for Sanofi in type 1 diabetes

Forxiga approved as add-on to insulin

- PMLiVE

Keytruda adds another NSCLC approval in Europe

Squamous NSCLC completes first-line dominance

- PMLiVE

Tecentriq gains first IO approval in triple negative breast cancer

A coup for Roche in IO field dominated by Keytruda

- PMLiVE

UK Biobank generates “largest open access resource of exome data”

Around 50,000 de-identifed genetic profiles available for research

- PMLiVE

Novartis and Syncona back new Swiss biotech Anaveon

Founders focused on IL-2 Receptor Agonists

- PMLiVE

Merck & Co to buy IO specialists Immune Design for $300m

US giant looks to next generation technology

- PMLiVE

More good news, and some bad, for Merck’s Keytruda

A rare setback in phase 3 liver cancer trial

- PMLiVE

Immuno-oncology in 2019: the rapid evolution continues

Immunotherapy is pharma’s biggest growth driver – how will it develop in 2019?

- PMLiVE

Immunotherapy combination trials Q&A

By Chris Learn and Martin Lachs

- PMLiVE

Keytruda combo outshines Opdivo in kidney cancer

BMS also on the backfoot after Nektar data release

- PMLiVE

Sanofi extends growth spurt thanks to Genzyme, Dupixent

US approval of Cablivi adds to good news

- PMLiVE

Sanofi gets US okay for $270,000 blood disorder drug Cablivi

First in a new class of single-domain antibody fragments drugs

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links